Added benefit of dapagliflozin is not proven

(Institute for Quality and Efficiency in Health Care) In an early benefit assessment IQWiG examined whether the drug dapagliflozin offers an added benefit over the current standard therapy for people with type 2 diabetes. However, no such added benefit can be derived from the dossier because the drug manufacturer did not present any suitable data for this comparison. This is the conclusion of a dossier assessment by the German IQWiG, Cologne, which was published in March 2013 and for which an English-language extract is now available.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news